Kiio competitors

Maria E. Bennett has led SPR Therapeutics since its inception. Prior to the formation of SPR, Maria Bennett served as the VP of Clinical Affairs at NDI Medical, LLC a medical device development company where she played a vital role in the development of a neurostimulation system addressing urinary incontinence, which was acquired by Medtronic in 2008 company for $42 million. Prior to joining NDI, Maria Bennett was a Clinical Project Manager at Boston Scientific, leading a team that conducted a large, multi-center clinical trial demonstrating safety and efficacy of an innovative angioplasty balloon, and achieving a 510(k) clearance for this product. Prior to this, she was the Manager of Clinical Studies and Director of Research and Development at NeuroControl Corp., where she co-developed a neurostimulation treatment for post-stroke shoulder pain. In 2009, she was selected by Springboard Enterprises as one of thirty female entrepreneurs from over 100 applicants to present at its LifeScience Venture Forums. She is the inventor of the Smartpatch™ System, having patents issued and pending. Maria Bennett holds a master's degree in biomedical engineering from Case Western Reserve University and a bachelor's degree from Miami University (OH) in engineering management.

Frank J. Bellizzi is a CEO at Concentric Analgesics, Inc. and is based in United States. He studied at Wharton School of the University of Pennsylvania between 1990 and 1993.

Greg Sullivan is a Medical Director at HEALTHCARE SERVICES GROUP INC, Lab Director at Parkway Medical Center, and Chief Executive Officer at Bridge Therapeutics and is based in Birmingham, Alabama. He attended University of Alabama at Birmingham, ENERNOC INC between 1979 and 1982, and Carraway Methodist Health Systems between 1983 and 1986.

Anthony P. Mack has more than 25 years of experience in the pharmaceutical and finance industries. Prior to founding Virpax in 2016, Mr. Mack founded Scilex Pharmaceuticals and served as President and CEO until February 2018. Scilex was sold to a publicly traded company. Mr. Mack founded his first pharmaceutical company ProSolus Pharmaceuticals in 2009, where he served as President before selling the company to Mission Pharmacal in 2015. Mr. Mack has held high-level management positions with Purdue Pharma, Endo Pharmaceuticals, Novartis, and EKR Therapeutics. He has led training, marketing, and commercial distribution for billion-dollar pain management products and has forged key strategic alliances. Mr. Mack has served as Founder, Director, and Executive Officer of both ProSolus Pharmaceuticals Inc. and Scilex Pharmaceuticals. Mr. Mack also founded IACTA Pharmaceuticals Inc and served as Director until March 15, 2021. By serving on executive boards, Mr. Mack has utilized his skills and experience to implement corporate governance policies and overall business strategy. Mr. Mack holds an Executive MBA in Pharmaceutical and Healthcare Marketing from Saint Joseph’s University.